Table 2 Summary of pooled risk ratios and subgroup analyses of INH efficacy
Groups | Number of studies | Number of participants | Fixed effects risk ratio(95% CI*) | Random effects risk ratio(95% CI) | Heterogeneity Chi 2( p) |
|---|---|---|---|---|---|
All studies | 8 | 10,320 | 0.65(0.47,0.89)# | 0.53(0.38,0.80) | 18.56(0.00968) |
High quality | 6 | 7,845 | 0.66(0.45,0.98) | 0.55(0.35,0.87) | 17.55(0.00357) |
Low quality | 2 | 2,474 | 0.53(0.30,0.94) | NA | 0.47(0.49303) |
HIV negative | 6 | 9,509 | 0.55(0.40,0.75) | 0.52(0.36,0.75) | 8.57(0.1277) |
HIV positive | 2 | 810 | 0.86(0.41,1.81) | 0.58(0.17,1.94) | 5.14(0.02335) |
TB endemic | 5 | 2,189 | 0.78(0.55,1.11) | 0.67(0.45,0.99) | 8.93(0.06281) |
TB non endemic | 3 | 8,130 | 0.40(0.27,0.57) | NA | 0.05(0.9736) |
Primary TB prophylaxis | 2 | 1,353 | 0.93(0.71,1.21) | NA | 0.23(0.63119) |
Secondary TB prophylaxis | 3 | 5,224 | 0.44(0.31,0.61) | NA | 1.05(0.59104) |
Excluding studies INH was initiated at age ≤4 months | 6 | 8,966 | 0.41(0.31,0.55) | NA | 1.84(0.87086) |
High quality excluding studies INH was initiated at age ≤4 months | 4 | 6,492 | 0.38(0.27.0.53) | NA | 0.43(0.93385) |
INH initiated at age ≤4 months | 2 | 1,353 | 0.93(0.71,1.21) | NA | 0.23(0.29) |
Age <5 years | 3 | 1,616 | 0.86(0.57,1.30) | 0.77(0.48,1.23) | 5.14(0.07644) |
Age 5–15 years | 2 | 2,474 | 0.53(0.30,0.94) | NA | 0.47(0.49303) |
INH for ≥6 months | 6 | 7,845 | 0.66(0.45,0.98) | 0.55(0.35,0.87) | 17.55(0.00357) |
INH for <6 months | 2 | 2,474 | 0.53(0.30,0.94) | NA | 0.47(0.49303) |